Xavier Hardy

Mintz

+ Follow Contact

Latest Posts › Constitutional Challenges

Share:

Appeals Court Rejects AstraZeneca’s Challenge to Medicare Drug Price Negotiation Program

A federal appellate court has handed down the first appellate-level decision addressing the merits of drug manufacturers’ challenges to the Inflation Reduction Act of 2022's (IRA) Medicare Drug Negotiation Program...more

5/13/2025 / Administrative Procedure Act , Appeals , Centers for Medicare & Medicaid Services (CMS) , Constitutional Challenges , Drug Pricing , Inflation Reduction Act (IRA) , Judicial Review , Medicare , Pharmaceutical Industry , Prescription Drugs

Mintz IRA Update — A Circuit Win and the End of Chevron Deference Could Shift Tides in Drug Price Negotiation Program Challenges

As detailed in our previous updates, the IRA’s Medicare Drug Price Negotiation Program (the Negotiation Program or Program), which enables the federal government to negotiate prices for some of the costliest Medicare Part D...more

2/14/2025 / Administrative Procedure Act , Centers for Medicare & Medicaid Services (CMS) , Chevron Deference , Constitutional Challenges , Loper Bright Enterprises v Raimondo , Medicare , Medicare Part D , Pharmaceutical Industry , Prescription Drugs , SCOTUS

Mintz IRA Update — IRA Litigation Update: Courts Begin to Address Legal Challenges to the Medicare Drug Price Negotiation Program

The IRA’s Medicare Drug Price Negotiation Program (the “Negotiation Program” or “Program”), which enables the federal government to negotiate prices for some of the costliest Medicare Part D drugs, has been subject to several...more

7/16/2024 / AstraZeneca , Centers for Medicare & Medicaid Services (CMS) , Constitutional Challenges , Dismissals , Drug Pricing , Fifth Amendment , Inflation Reduction Act (IRA) , Infringement , Medicare , Negotiations

3 Results

View per page

Page: of 1